Haemonetics Financial Statements From 2010 to 2025

HAE Stock  USD 49.26  0.29  0.59%   
Haemonetics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Haemonetics' valuation are provided below:
Gross Profit
791.1 M
Profit Margin
0.1214
Market Capitalization
2.4 B
Enterprise Value Revenue
2.4425
Revenue
1.3 B
There are over one hundred nineteen available fundamental trends for Haemonetics, which can be analyzed over time and compared to other ratios. Investors should ensure to confirm all of Haemonetics' regular performance against the performance from 2010 to 2025 to make sure the company is sustainable down the road.

Haemonetics Total Revenue

1.43 Billion

Check Haemonetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Haemonetics' main balance sheet or income statement drivers, such as Interest Expense of 13.7 M, Total Revenue of 1.4 B or Gross Profit of 786.4 M, as well as many indicators such as Price To Sales Ratio of 4.27, Dividend Yield of 0.0098 or PTB Ratio of 5.13. Haemonetics financial statements analysis is a perfect complement when working with Haemonetics Valuation or Volatility modules.
  
Build AI portfolio with Haemonetics Stock
Check out the analysis of Haemonetics Correlation against competitors.
For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.

Haemonetics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding42.5 M50.7 M51.5 M
Slightly volatile
Total Assets2.6 B2.5 B1.5 B
Slightly volatile
Short and Long Term Debt Total1.3 B1.2 B540.5 M
Slightly volatile
Other Current Liabilities172.4 M164.2 M105.3 M
Slightly volatile
Total Current Liabilities607 M578.1 M280.5 M
Slightly volatile
Total Stockholder Equity546.7 M820.8 M709.6 M
Slightly volatile
Property Plant And Equipment Net189.6 M284.1 M267.3 M
Slightly volatile
Retained Earnings285 M352.2 M277.1 M
Pretty Stable
Accounts Payable35.3 M67 M49.8 M
Slightly volatile
Cash322.1 M306.8 M190.6 M
Slightly volatile
Non Current Assets Total1.6 B1.5 B918 M
Slightly volatile
Non Currrent Assets Other101.6 M164.1 M174 M
Slightly volatile
Cash And Short Term Investments322.1 M306.8 M190.6 M
Slightly volatile
Net Receivables123.7 M202.7 M153.7 M
Slightly volatile
Liabilities And Stockholders Equity2.6 B2.5 B1.5 B
Slightly volatile
Non Current Liabilities Total1.1 B1.1 B533.3 M
Slightly volatile
Inventory383.4 M365.1 M229.3 M
Slightly volatile
Other Current Assets56.6 M60.4 M67.6 M
Very volatile
Other Stockholder Equity283.1 M523.3 M456.4 M
Slightly volatile
Total Liabilities1.7 B1.6 B813.8 M
Slightly volatile
Property Plant And Equipment Gross879.1 M837.2 M463 M
Slightly volatile
Total Current Assets981.7 M935 M625.2 M
Slightly volatile
Short Term Debt318.7 M303.6 M87.5 M
Slightly volatile
Intangible Assets478.5 M455.7 M248.4 M
Slightly volatile
Common Stock Total Equity421 K579.6 K479.2 K
Slightly volatile
Common Stock423.5 K482 K475.3 K
Slightly volatile
Other Liabilities131.1 M124.9 M61.7 M
Slightly volatile
Other Assets950100019.4 M
Very volatile
Long Term Debt967.3 M921.2 M456 M
Slightly volatile
Good Will634.5 M604.3 M340.3 M
Slightly volatile
Property Plant Equipment226.7 M331.5 M278.5 M
Slightly volatile
Retained Earnings Total Equity230.9 M227.9 M279 M
Slightly volatile
Long Term Debt Total461.3 M921.2 M422 M
Slightly volatile
Capital Surpluse532.6 M523.3 M487.2 M
Slightly volatile
Deferred Long Term Liabilities26.4 M41.6 M26.1 M
Slightly volatile
Non Current Liabilities Other57 M68.2 M52.1 M
Slightly volatile
Deferred Long Term Asset Charges3.3 MM3.5 M
Slightly volatile
Short and Long Term Debt318.7 M303.6 M190.7 M
Slightly volatile
Cash And Equivalents225.9 M306.8 M182 M
Slightly volatile
Net Invested Capital1.2 BB1.1 B
Slightly volatile
Net Working Capital399.1 M356.9 M266.1 M
Slightly volatile
Capital Stock403.1 K482 K500.6 K
Slightly volatile
Capital Lease Obligations6.2 M6.5 M43.6 M
Slightly volatile

Haemonetics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Total Revenue1.4 B1.4 B963.3 M
Slightly volatile
Gross Profit786.4 M749 M481.3 M
Slightly volatile
EBITDA354.3 M337.4 M183.2 M
Slightly volatile
Depreciation And Amortization121.4 M115.6 M86.8 M
Slightly volatile
Other Operating Expenses588 M1.1 B795.2 M
Slightly volatile
Cost Of Revenue339.9 M611.9 M468 M
Slightly volatile
Total Operating Expenses266.2 M527.1 M363.4 M
Slightly volatile
Research Development34.4 M62.7 M42.5 M
Slightly volatile
Selling General Administrative244 M436.8 M304.9 M
Slightly volatile
Selling And Marketing Expenses4.8 M8.2 M4.7 M
Slightly volatile
Non Recurring630.4 K663.5 K20.4 M
Pretty Stable
Interest Income13.2 M9.7 M11.3 M
Slightly volatile
Reconciled Depreciation109.6 M115.6 M95.7 M
Slightly volatile

Haemonetics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Free Cash Flow149.6 M142.4 M80 M
Slightly volatile
Begin Period Cash Flow132.1 M178.8 M171.8 M
Slightly volatile
Depreciation121.4 M115.6 M86.8 M
Slightly volatile
Capital Expenditures54 M39.3 M71.7 M
Very volatile
Total Cash From Operating Activities109.7 M181.7 M145.8 M
Slightly volatile
End Period Cash Flow322.1 M306.8 M190.6 M
Slightly volatile
Change To Netincome40.4 M41.6 M38.5 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.272.33712.9237
Slightly volatile
Dividend Yield0.00980.0110.012
Slightly volatile
PTB Ratio5.133.87453.9686
Slightly volatile
Days Sales Outstanding61.0654.356660.0311
Slightly volatile
Book Value Per Share14.2616.309114.6026
Slightly volatile
Free Cash Flow Yield0.03770.04480.0407
Pretty Stable
Operating Cash Flow Per Share4.183.61073.9558
Slightly volatile
Stock Based Compensation To Revenue0.01440.02180.0163
Slightly volatile
Capex To Depreciation0.840.33980.9144
Pretty Stable
PB Ratio5.133.87453.9686
Slightly volatile
EV To Sales4.353.01173.2446
Slightly volatile
Free Cash Flow Per Share2.762.83032.3737
Slightly volatile
Inventory Turnover3.061.67572.4041
Slightly volatile
Days Of Inventory On Hand119218158
Slightly volatile
Payables Turnover8.99.13259.8164
Slightly volatile
Sales General And Administrative To Revenue0.370.34670.3314
Very volatile
Research And Ddevelopement To Revenue0.04340.04610.0438
Pretty Stable
Capex To Revenue0.08270.02890.0816
Slightly volatile
Cash Per Share3.426.0954.1838
Slightly volatile
POCF Ratio17.5217.500914.6452
Slightly volatile
Payout Ratio0.190.220.2347
Slightly volatile
Capex To Operating Cash Flow0.340.21610.4056
Slightly volatile
PFCF Ratio26.5222.326624.7135
Pretty Stable
Days Payables Outstanding41.039.967338.1813
Slightly volatile
EV To Operating Cash Flow17.8522.552616.3847
Slightly volatile
EV To Free Cash Flow27.0228.771227.4711
Slightly volatile
Intangibles To Total Assets0.30.43250.3367
Slightly volatile
Net Debt To EBITDA0.482.72092.0384
Very volatile
Current Ratio1.351.61732.4871
Pretty Stable
Receivables Turnover5.986.71496.1294
Slightly volatile
Graham Number16.6534.964927.2907
Slightly volatile
Shareholders Equity Per Share14.2616.309114.6026
Slightly volatile
Debt To Equity0.341.49210.7407
Slightly volatile
Capex Per Share1.420.78041.5821
Pretty Stable
Revenue Per Share17.1327.03819.865
Slightly volatile
Interest Debt Per Share4.8924.528811.59
Slightly volatile
Debt To Assets0.210.49970.3323
Slightly volatile
Enterprise Value Over EBITDA25.712.146822.753
Slightly volatile
Short Term Coverage Ratios1.130.59879.9184
Slightly volatile
Operating Cycle180272218
Slightly volatile
Price Book Value Ratio5.133.87453.9686
Slightly volatile
Days Of Payables Outstanding41.039.967338.1813
Slightly volatile
Dividend Payout Ratio0.190.220.2347
Slightly volatile
Price To Operating Cash Flows Ratio17.5217.500914.6452
Slightly volatile
Price To Free Cash Flows Ratio26.5222.326624.7135
Pretty Stable
Ebt Per Ebit1.060.95611.1081
Slightly volatile
Effective Tax Rate0.240.20930.1457
Slightly volatile
Company Equity Multiplier1.642.98592.0968
Slightly volatile
Long Term Debt To Capitalization0.07320.52880.3567
Slightly volatile
Total Debt To Capitalization0.250.59870.4004
Slightly volatile
Debt Equity Ratio0.341.49210.7407
Slightly volatile
Quick Ratio0.940.98571.6393
Pretty Stable
Dividend Paid And Capex Coverage Ratio2.954.62662.6218
Slightly volatile
Net Income Per E B T0.760.79070.8546
Slightly volatile
Cash Ratio0.470.53060.8104
Pretty Stable
Cash Conversion Cycle139232180
Slightly volatile
Operating Cash Flow Sales Ratio0.240.13350.1992
Pretty Stable
Days Of Inventory Outstanding119218158
Slightly volatile
Days Of Sales Outstanding61.0654.356660.0311
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.660.78390.5944
Slightly volatile
Cash Flow Coverage Ratios0.870.14840.4419
Slightly volatile
Price To Book Ratio5.133.87453.9686
Slightly volatile
Fixed Asset Turnover2.724.79083.4175
Slightly volatile
Capital Expenditure Coverage Ratio2.954.62662.6218
Slightly volatile
Price Cash Flow Ratio17.5217.500914.6452
Slightly volatile
Enterprise Value Multiple25.712.146822.753
Slightly volatile
Debt Ratio0.210.49970.3323
Slightly volatile
Cash Flow To Debt Ratio0.870.14840.4419
Slightly volatile
Price Sales Ratio4.272.33712.9237
Slightly volatile
Asset Turnover0.730.55520.6596
Slightly volatile
Gross Profit Margin0.460.55040.49
Slightly volatile
Price Fair Value5.133.87453.9686
Slightly volatile

Haemonetics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.7 B1.6 B1.9 B
Slightly volatile
Enterprise Value1.5 B1.4 B1.8 B
Slightly volatile

Haemonetics Fundamental Market Drivers

Forward Price Earnings10.0402
Cash And Short Term Investments306.8 M

Haemonetics Upcoming Events

8th of February 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
9th of May 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of March 2023
Last Financial Announcement
View

About Haemonetics Financial Statements

Haemonetics stakeholders use historical fundamental indicators, such as Haemonetics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Haemonetics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Haemonetics' assets and liabilities are reflected in the revenues and expenses on Haemonetics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Haemonetics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue43.3 M23.8 M
Total Revenue1.4 B1.4 B
Cost Of Revenue611.9 M339.9 M
Stock Based Compensation To Revenue 0.02  0.01 
Sales General And Administrative To Revenue 0.35  0.37 
Research And Ddevelopement To Revenue 0.05  0.04 
Capex To Revenue 0.03  0.08 
Revenue Per Share 27.04  17.13 
Ebit Per Revenue 0.16  0.06 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports:
Check out the analysis of Haemonetics Correlation against competitors.
For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.
You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.05)
Earnings Share
3.27
Revenue Per Share
27.126
Quarterly Revenue Growth
(0.04)
Return On Assets
0.0652
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.